AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11564386
Drug: Cerivastatin 0.3
RxNorm normalized name: cerivastatin 0.3 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerivastatin 0.3 mg once daily
Trial: 9784902
Drug: Nicotinell (nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinell (nicotine patches)
Trial: 3555877
Drug: 0.06 mg
RxNorm normalized name: urea 0.06 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.06 mg X kg‐1 d‐tubo‐curarine (dTc) IV three minutes prior and normal saline IV immediately prior
Trial: 3555877
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline IV three minutes prior and 1.5 mg X kg‐1 lidocaine IV immediately prior
Trial: 3555877
Drug: 0.06 mg
RxNorm normalized name: urea 0.06 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.06 mg X kg‐1 dTc IV three minutes prior and 1.5 mg X kg‐1 lidocaine IV immediately prior
Trial: 30146493
Drug: External expert
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External expert consultation model (workshop, therapy manual, expert follow-up consultation)
Trial: 16911730
Drug: Cue exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cue exposure therapy (CET)
Trial: 17230050
Drug: Placebo psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo psychotherapy treatment (PPT)
Trial: 15302737
Drug: Fondaparinux (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux (2.5 mg once daily)
Trial: 10225047
Drug: 3 week
RxNorm normalized name: Camrese 13 Week Extended-Day Tablet Dispenser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 week course of 70 degrees head-up tilt for 30 min daily (Group-I)
Trial: 10225047
Drug: Specific yogic
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific yogic exercises equivalent to head-up or head-down tilt for 30 min daily (Group-II)
Trial: 27027501
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + AMX + MET (500 mg × 3 times daily for 3 days)
Trial: 27027501
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + AMX + MET (500 mg × 3 times daily for 7 days)
Trial: 23535525
Drug: ABBS±ACE‐I (Aspirin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBS±ACE‐I (Aspirin, Beta-blockers, Statins, with/without Angiotensin-converting enzyme inhibitor) (n=513)
Trial: 23535525
Drug: Aspirin (A)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (A)
Trial: 17190733
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitor (ACE-I)
Trial: 20883265
Drug: Mesotherapy administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesotherapy administration of meglumine antimoniate
Trial: 20883265
Drug: Conventional injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional injection of meglumine antimoniate
Trial: 12622937
Drug: Meropenem 500
RxNorm normalized name: meropenem 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 500 mg every 12 hours (or 1 g every 12 hours if necessary)
Trial: 12622937
Drug: Imipenem/cilastatin 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin 500 mg/500 mg every 12 hours (or 1 g every 12 hours if necessary)
Trial: 10626827
Drug: Acetate-free biofiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetate-free biofiltration (AFB) with AN69 membrane and bicarbonate solution infusion (NaHCO3 145 or 167 mEq/lt)
Trial: 6452802
Drug: Amitriptyline 75
RxNorm normalized name: amitriptyline 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 75 mg nocte (increasing to 150 mg nocte)
Trial: 6452802
Drug: Zimelidine 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zimelidine 100 mg nocte (increasing to 200 mg nocte)
Trial: 31969173
Drug: Low-dose inhaled
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose inhaled nitric oxide (5-10 ppm)
Trial: 30589351
Drug: Treatment integrity
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment integrity procedures
Trial: 25644360
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no MSF, 500 mL of water)
Trial: 19523094
Drug: Traditional management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional management (oral intake of clear fluids allowed after passage of flatus and regular diet with the passage of bowel movement)
Trial: 17135064
Drug: Hypnosis (standardized,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypnosis (standardized, individual 8‐session hypnosis treatment)
Trial: 11466161
Drug: Controlled-release lovastatin
RxNorm normalized name: lovastatin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release lovastatin 10 mg
Trial: 11466161
Drug: Controlled-release lovastatin
RxNorm normalized name: lovastatin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release lovastatin 20 mg
Trial: 11466161
Drug: Controlled-release lovastatin
RxNorm normalized name: lovastatin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release lovastatin 40 mg
Trial: 11466161
Drug: Controlled-release lovastatin
RxNorm normalized name: lovastatin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release lovastatin 60 mg
Trial: 10460956
Drug: Educational program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational program of 2 hours duration implemented twice a year
Trial: 10460956
Drug: Educational program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational program plus a 0.12% chlorhexidine rinse weekly
Trial: 10460956
Drug: Educational program,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational program, chlorhexidine rinse, and fluoride varnish application twice a year
Trial: 290649
Drug: Stannous fluoride
RxNorm normalized name: Stannous Fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stannous fluoride compounds
Trial: 290649
Drug: Placebo compounds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo compounds
Trial: 20025830
Drug: Peanut supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut supplementation (about 77 g) with habitual diet for 4 weeks
Trial: 18367384
Drug: APTD +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APTD + L-DOPA
Trial: 1353933
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ridazolol
Trial: 1353933
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg ridazolol
Trial: 1353933
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg ridazolol
Trial: 1353933
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg ridazolol
Trial: 6355394
Drug: Relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation therapy with spouse
Trial: 6355394
Drug: Relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation therapy alone
Trial: 6355394
Drug: Relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation therapy (both groups)
Trial: 24732289
Drug: Sutezolid 600
RxNorm normalized name: Sutezolid
DrugBank: Sutezolid (DB11905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sutezolid 600 mg BID
Trial: 24732289
Drug: Sutezolid 1200
RxNorm normalized name: Sutezolid
DrugBank: Sutezolid (DB11905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sutezolid 1200 mg QD
Trial: 24732289
Drug: Standard 4-drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 4-drug therapy
Trial: 23193905
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia with propofol‐remifentanil hydrochloride (PR)
Trial: 15793649
Drug: Topical 0.2
RxNorm normalized name: coal tar topical 0.2% topical soap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.2 percent glyceryl trinitrate paste, applied to the lower anal canal, three times daily for eight weeks.
Trial: 8867904
Drug: Gliclazide, 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide, 160 mg/24 h
Trial: 8867904
Drug: Placebo (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (in association with standard insulin treatment)
Trial: 1346491
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition plus somatostatin (group B)
Trial: 1346491
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition alone (group A)
Trial: 6378491
Drug: Frusemide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide (40 mg for 3 days) with high salt intake (Na+ intake 270 mmol/day)
Trial: 6378491
Drug: Frusemide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide (40 mg for 3 days) with low salt intake (Na+ intake 20 mmol/day)
Trial: 6378491
Drug: Frusemide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide (40 mg for 3 days) with high salt intake plus captopril (25 mg/6 h)
Trial: 21680809
Drug: Daily sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily sildenafil (50 mg)
Trial: 17439902
Drug: IFNbeta treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNbeta treatment
Trial: 17439902
Drug: Any relapse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any relapse during treatment
Trial: 12468916
Drug: Mega-dose methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mega-dose methylprednisolone therapy
Trial: 31365800
Drug: Transfusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfusion of 30 ml per kilogram
Trial: 31365800
Drug: Transfusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfusion of 20 ml per kilogram
Trial: 26758026
Drug: Cognitive Orientation
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Orientation to daily Occupational Performance (CO-OP) training focused on identifying effective cognitive strategies to increase motor competence, 9 sessions of 45 min each over 9 weeks.
Trial: 19965584
Drug: 1.7 g
RxNorm normalized name: Vaporizer 1.7 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.7 g DHA plus 0.6 g EPA
Trial: 18182992
Drug: Lower-dose ghrelin
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose ghrelin (2 microg kg(‐1))
Trial: 18182992
Drug: Upper-dose ghrelin
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Upper-dose ghrelin (8 microg kg(‐1))
Trial: 17259127
Drug: Epi-CH (activated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epi-CH (activated charcoal-epirubicin suspension)
Trial: 17259127
Drug: Control (aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (aqueous epirubicin injection)
Trial: 9172969
Drug: tianeptine 37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tianeptine 37.5 mg/day
Trial: 8258031
Drug: Oral zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zinc acetate supplementation (600 mg/day) in addition to standard therapy
Trial: 8258031
Drug: Only standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only standard therapy (a diet containing 0.8 g/kg/day of protein and 90 g/day of lactulose)
Trial: 3899084
Drug: Plain DTP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain DTP vaccine
Trial: 3899084
Drug: Adsorbed DTP
RxNorm normalized name: DTP-348
DrugBank: DTP-348 (DB12741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adsorbed DTP vaccine
Trial: 27455166
Drug: Antibiotics for
RxNorm normalized name: ANTIBIOTICS FOR TOPICAL USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics for a minimum of 5 days, stopped if body temperature was 37.8°C or less for 48 hours and no more than 1 CAP-associated sign of clinical instability.
Trial: 27455166
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treatment duration determined by physicians.
Trial: 18417275
Drug: Cetrorelix 10mg
RxNorm normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetrorelix 10mg every 2 weeks for 2 doses
Trial: 9162304
Drug: Low-fat, high-fiber,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat, high-fiber, high-vegetable and -fruit dietary pattern (20% of total energy intake, 18 g/1000 kcal, 5-8 servings daily)
Trial: 8185335
Drug: HCFU (long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCFU (long-term administration after radical treatment)
Trial: 8185335
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (radical treatment only)
Trial: 3241278
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nifedipine and enalapril
Trial: 3241278
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nifedipine with sodium restriction or hydrochlorothiazide
Trial: 29404979
Drug: Hyperfractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiation (HFX) of 72.0 Gy in 60 fractions given twice daily
Trial: 29404979
Drug: Standard radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard radiation of 60.0 Gy in 30 fractions given once daily
Trial: 19751084
Drug: Supportive-expressive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive-expressive group therapy with hypnosis plus education
Trial: 17273833
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine 0.5% (15 mg)
Trial: 17273833
Drug: Hyperbaric prilocaine
RxNorm normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperbaric prilocaine 2% (60 mg)
Trial: 14745746
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (anastrozole, tamoxifen alone or combined)
Trial: 8554360
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard inpatient treatment)
Trial: 2528578
Drug: Isradipine (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (7.5 mg twice daily)
Trial: 329522
Drug: Sisomicin administered
RxNorm normalized name: sisomicin
DrugBank: Sisomicin (DB12604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sisomicin administered twice daily
Trial: 329522
Drug: Gentamicin administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin administered three times daily
Trial: 23904282
Drug: Metreleptin administration
RxNorm normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metreleptin administration
Trial: 18819901
Drug: Local mild
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local mild hypothermia therapy (LMH group)
Trial: 18819901
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment (RT group)
Trial: 12707230
Drug: Transendocardial injections
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TRANSENDOCARDIAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transendocardial injections of autologous mononuclear bone marrow cells (15 injections of 0.2 cc)
Trial: 12707230
Drug: Transendocardial injections
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TRANSENDOCARDIAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transendocardial injections of autologous mononuclear bone marrow cells
Trial: 2206005
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment at a dose of 0.27 IU/kg (0.1 mg/kg) three times weekly for 6 months
Trial: 2206005
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment continued for another 6 months after initial treatment
Trial: 2206005
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of GH after 12 months of treatment
Trial: 30687503
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplements (ONS) providing 600 kcal and 22 g protein a day
Trial: 30687503
Drug: Between-meal snacks
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Between-meal snacks providing 600 kcal and 22 g protein a day
Trial: 27621045
Drug: Non-LARC prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-LARC prescription methods
Trial: 27052067
Drug: Alfentanil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (10 μg/kg)
Trial: 21110174
Drug: Acupoint catgut-embedding
RxNorm normalized name: CATGUT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint catgut-embedding therapy
Trial: 21110174
Drug: Fufuchun Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fufuchun Capsule (control)
Trial: 17425514
Drug: High-salt diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-salt diet (200 mmol sodium daily)
Trial: 17425514
Drug: Low-salt diet
RxNorm normalized name: Low-energy diets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-salt diet (20 mmol sodium daily)
Trial: 12160582
Drug: Conventional external
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional external irradiation with agonist analogue of gonadotropin-releasing hormone
Trial: 12160582
Drug: Conventional external
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional external irradiation without agonist analogue of gonadotropin-releasing hormone
Trial: 7601292
Drug: Combined alpha-
RxNorm normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined alpha- and beta-adrenoceptor blocking agent
Trial: 2696207
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine solution infiltration anesthesia
Trial: 26732187
Drug: Intensive nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive nutritional education aimed at salt restriction to 6 g/d by nutritionists
Trial: 25312265
Drug: Sufentanil (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil (0.2 μg/kg, n = 24)
Trial: 16339612
Drug: Guideline-level depression
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-level depression care (antidepressant use or specialty counseling)
Trial: 6139668
Drug: Heat-inactivated hepatitis
RxNorm normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-inactivated hepatitis B vaccine (3 micrograms of surface antigen) given at 0, 1, 2, and 5 months
Trial: 31931932
Drug: Propranolol (0.5‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (0.5‐3 mg/Kg body weight per day)
Trial: 26224232
Drug: Topical antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antioxidant cream
Trial: 24479524
Drug: Chloroquine chemoprophylaxis
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine chemoprophylaxis and three intradermal doses of aseptic, purified Plasmodium falciparum sporozoites.
Trial: 24479524
Drug: Atovaquone/proguanil (Malarone®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atovaquone/proguanil (Malarone®) treatment initiated on day 11 post-CHMI.
Trial: 9762658
Drug: CSF-enriched antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSF-enriched antibodies
Trial: 3397807
Drug: Combination met‐hGH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination met‐hGH plus oxandrolone
Trial: 31883847
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with mucosal grass pollen allergen exposure
Trial: 29238967
Drug: Anabasum 5
RxNorm normalized name: Anabasum
DrugBank: Lenabasum (DB12193)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anabasum 5 mg